Lithea, a biotechnology firm based in Lund, Sweden, has successfully raised €851,000 from existing investors to further its development of a targeted drug delivery system for treating childhood bone cancer. This funding will support the ongoing advancement of their lead product, LIT1001, which aims to deliver medication directly into tumors.
The company specializes in innovative cancer therapies that enhance treatment efficacy by minimizing systemic exposure. With this latest investment, Lithea is poised to prepare LIT1001 for clinical trials, a crucial step in bringing its therapeutic approach to market. The funding follows a series of encouraging developments for the company, underscoring the growing support for novel cancer treatments.
Lithea’s advancements could significantly impact pediatric oncology, particularly in treating conditions like osteosarcoma, which predominantly affects children and adolescents. By focusing on localized drug delivery, Lithea aims to improve patient outcomes while reducing side effects associated with conventional chemotherapy.
Source: Swedish Tech News
Leave feedback about this
You must be logged in to post a comment.